Information Update: Xigris (drotrecogin alfa) Withdrawn Worldwide

(firmenpresse) - OTTAWA, ONTARIO -- (Marketwire) -- 10/25/11 -- Health Canada is informing Canadians that it is working with Eli Lilly Canada, Inc. to withdraw the drug Xigris (drotrecogin alfa) from the Canadian market, in light of the company's decision to withdraw Xigris from the market worldwide.

Xigris is used solely in hospital intensive care units to treat patients at a high risk of death due to serious complications of a blood infection (called sepsis or septic shock). Sepsis is a serious medical condition involving infection and generalized inflammation. The body's normal response to an infection is to set off a limited chain reaction to fight the infection. In severe sepsis, this systemic immune response becomes overactive and can result in damage to vital body organs, leading to bleeding, organ failure and, in many cases, to death. Xigris is used in serious cases only, in addition to other sepsis treatments.

The withdrawal is in light of a large international clinical trial, known as the PROWESS-SHOCK study that showed no benefit for patients receiving Xigris compared to patients who did not receive it.

Health Canada is working with Eli Lilly Canada, Inc. to facilitate the withdrawal in Canada. Additional information on the withdrawal will be communicated to hospitals as soon as it is available.

Eli Lilly Canada, Inc. has also issued a news release () with information on the recall. Physicians, caregivers or patients with additional questions about Xigris can contact the company directly at 1-800-LillyRx (1-800-545-5979) or .

How to report side effects to health products

To report suspected adverse reaction to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or complete a () and send to us using one of these methods:

Fax: 1-866-678-6789

Internet:

Mail ( ()):

Egalement disponible en francais

Contacts:
Media Inquiries:
Health Canada
(613) 957-2983

Public Inquiries:
(613) 957-2991
1-866 225-0709

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 25.10.2011 - 13:16 Uhr
Sprache: Deutsch
News-ID 79898
Anzahl Zeichen: 0

contact information:
Town:

OTTAWA, ONTARIO

Kategorie:

Government & Administration

Diese Pressemitteilung wurde bisher 267 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Information Update: Xigris (drotrecogin alfa) Withdrawn Worldwide"
steht unter der journalistisch-redaktionellen Verantwortung von

Health Canada (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Media Advisory: Health Canada ...

OTTAWA, ONTARIO -- (Marketwired) -- 12/16/13 -- Parliamentary Secretary Eve Adams, on behalf of Rona Ambrose, Minister of Health, along with a toy safety expert from Health Canada`s Consumer Product Safety Division, will hold a demonstration on sma ...

Consumer Product Alert: Health Canada Urges Parents to Safeguard Children from C ...

OTTAWA, ONTARIO -- (Marketwired) -- 12/11/13 -- Issue:Health Canada is urging parents and caregivers to safeguard children against the strangulation hazard posed by products with cords. While exploring their natural environment, children can become ...

Use a Digital Food Thermometer for Safe Cooking ...

OTTAWA, ONTARIO -- (Marketwired) -- 12/10/13 -- The only reliable way to make sure that meat, poultry, fish and seafood dishes reach safe internal cooking temperatures before serving is to use a digital food thermometer.While we often look for other ...

Alle Meldungen von Health Canada